UNSPSC 51401528: Flutazolam

This classification denotes a benzodiazepine with the molecular formula C19H18ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5G2K7O5D8S, chemically known as 10-chloro-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)oxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as flutazolam, which bears US NIH Compound Identifier 3398. European Medicines Agency schedules Flutazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07757MIG.

UNSPSC 51401528 Flutazolam (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally denotes a specific benzodiazepine pharmaceutical, but the recent opportunities tagged under it involve naloxone, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals—none of which correspond to flutazolam procurement. State and local health agencies, cooperative purchasing alliances, and counties are soliciting through various notices (IFB, RFI, RFP), but the mismatch between the code's specificity and the actual work being bought suggests the code carries little relevant activity for vendors focused on flutazolam supply.

Issuing bodies active in the broader pharmaceutical-procurement space include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multistate public-sector networks (Minnesota MMCAP, spanning Minnesota and Oregon). Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, with quarterly deliveries), Texas HHS's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026 through June 30, 2028). No opportunities specifically for flutazolam appear in the recent record. Vendors pursuing pharmaceutical-supply contracts in the state and local space should monitor the broader codes under which generic drugs, branded pharmaceuticals, and health-system supply categories are organized rather than rely on this Commodity code.